|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM155374893 |
| 003 |
DE-627 |
| 005 |
20231223072008.0 |
| 007 |
tu |
| 008 |
231223s2005 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0518.xml
|
| 035 |
|
|
|a (DE-627)NLM155374893
|
| 035 |
|
|
|a (NLM)15893693
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Tiberti, Claudio
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a IA-2 combined epitope assay
|b a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes
|
| 264 |
|
1 |
|c 2005
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.07.2005
|
| 500 |
|
|
|a Date Revised 29.01.2022
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Islet tyrosine phosphatase 2 (IA-2) is one of the major autoantigens in type 1 diabetes. The aim of this work was to evaluate which IA-2 construct(s) among those usually employed has the highest sensitivity and specificity for detecting IA-2 autoantibodies in autoimmune diabetes and whether the combination of different IA-2 constructs into a single assay allows the detection of immunoreactivities otherwise not detectable by a single construct. For this purpose, we tested the single immunoreactivities of IA-2 FL(aa 1-979), IA-2(BDC)(aa 256-556:630-979), IA-2 IC(aa 605-979), IA-2(aa 256-760), IA-2(aa 761-928), and of 7 combinations of these fragments in the sera of 203 newly diagnosed type 1 diabetic patient (DM: 109 males,94 females, mean age 12.9 +/- 7.5 years) and 43 prediabetic subject (PDM: 20 males, 23 females, mean age 10.3 +/- 6.0 years) sera. IA-2 IC was the single construct that showed the highest sensitivity and specificity both in DM and PDM subjects; however, all of the other IA-2 constructs investigated detected additional immunoreactivities with respect to it. The combined use into the same assay of IA-2 IC, IA-2 FL, and IA-2 (256-760) constructs allowed detection of IA-2 Abs in additional 13.3% DM and 30.4% PDM subjects compared to the single IA-2 IC construct, suggesting this methodology as a new, highly sensitive approach to the study of IA-2 autoimmunity in type 1 diabetes
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a Epitopes
|2 NLM
|
| 650 |
|
7 |
|a Membrane Proteins
|2 NLM
|
| 650 |
|
7 |
|a Protein Phosphatase 2
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.16
|2 NLM
|
| 650 |
|
7 |
|a PTPRN2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.48
|2 NLM
|
| 650 |
|
7 |
|a Protein Tyrosine Phosphatase, Non-Receptor Type 1
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.48
|2 NLM
|
| 650 |
|
7 |
|a Protein Tyrosine Phosphatases
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.48
|2 NLM
|
| 650 |
|
7 |
|a Receptor-Like Protein Tyrosine Phosphatases, Class 8
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.48
|2 NLM
|
| 700 |
1 |
|
|a Verrienti, Antonella
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fiore, Benedetta
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Liping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Eisenbarth, George S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dotta, Francesco
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Di Mario, Umberto
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 115(2005), 3 vom: 31. Juni, Seite 260-7
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:115
|g year:2005
|g number:3
|g day:31
|g month:06
|g pages:260-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 115
|j 2005
|e 3
|b 31
|c 06
|h 260-7
|